Full-Time

Senior Clinical Research Associate

Posted on 2/21/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$105.8k - $140.8k/yr

+ Annual Bonus Eligibility + Incentive Compensation Plan Eligibility + Equity Awards + Employee Stock Purchase Plan

Remote in USA

Hybrid

Up to 60% travel within the U.S.; remote work allowed.

Category
Biology & Biotech (2)
,
Required Skills
Google Cloud Platform
Requirements
  • Understands clinical trial processes with a thorough knowledge of ICH and associated regulatory guidelines
  • Minimum of 4-6 years of relevant Clinical Operations experience
  • Minimum of 3-4 years of (CRA) monitoring experience in the pharmaceutical or CRO Industry
  • BS/BA in a relevant scientific discipline
  • Minimum of 4-6 years of relevant Clinical Operations experience and minimum of 3-4 years of monitoring experience (education line reiterates)
  • Travel up to 40-60% time
  • Efficient in Microsoft Word, Excel, PowerPoint and Outlook
  • Familiar with industry Clinical Trial Management System and data management systems
  • Minimum of 4-6 years of relevant Clinical Operations experience
  • Experience in global oncology trials preferred
Responsibilities
  • Perform and coordinate assigned aspects of the clinical monitoring process in accordance with GCPs and SOPs to assess the safety and efficacy of investigational products and/or medical devices
  • Conduct site visits to determine protocol and regulatory compliance, and prepare required documentation
  • Develop collaborative relationships with investigative sites, and study vendors
  • Track enrollment status reports to ensure study sites stay on track to meet enrollment goals
  • Track study-specific status reports to ensure all required information regarding site issues, deviations, and CRF status are kept current by the monitoring team
  • Serve as mentor/trainer for less experienced CRAs to assist with general and study-specific monitoring issues
  • Provide direct support to the Clinical Study Manager by assisting with monitoring visit report review and other managerial tasks as needed
  • Perform study-specific training with project team
  • Develop study-specific monitoring tools and forms for use by monitoring team to assist in efficient review of study data
  • Perform Serious Adverse Event (SAE) reconciliation and work with study sites and CRAs to resolve discrepancies
  • Review outstanding data reports and work with CRAs to ensure data collection is met per contractual guidelines
  • Works with Clinical Trial Oversight Managers (CTOMs) and Clinical Study Team (CST) to manage site trends through dashboard review and ongoing risk assessment to ensure quality standards and address concerns associated with study delivery at sites within established protocols and portfolio under general supervision
  • Collaborates with CST and clinical study sites to ensure timely delivery of study milestones (i.e., study startup, recruitment, database analyses, closeout, etc.).
  • Provide support for study sites, and CRAs with audits/inspections preparation/responses and quality issues, as needed, and follow-through with audit/inspection findings to resolution as it related to involved CRA staff.
  • Assist with other assigned clinical responsibilities within scope of role to provide best practice and/or support to junior clinical staff.
Desired Qualifications
  • Experience in global oncology trials preferred
  • Global Competencies list items are general - not included as desirable

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Brukinsa generated $1.1 billion in first-quarter 2026 sales, up 38%.
  • Sonrotoclax won FDA accelerated approval for relapsed or refractory mantle cell lymphoma.
  • TEVIMBRA plus ZIIHERA holds FDA Priority Review for HER2-positive gastric cancer.

What critics are saying

  • Revenue remains heavily dependent on Brukinsa, exposing BeOne to competitive erosion.
  • Sonrotoclax's approval depends on CELESTIAL-RRMCL confirmatory results.
  • TEVIMBRA diversification is unproven, with revenue still trailing Brukinsa materially.

What makes BeOne unique

  • BeOne combines Brukinsa, Tevimbra, and sonrotoclax across blood and solid tumors.
  • Its global trial network spans 30,000 patients and 75 approval markets.
  • Brukinsa remains the only BTK inhibitor with head-to-head PFS superiority.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-19%

2 year growth

-13%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE